Literature DB >> 16850244

Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.

Guillermo Carreño1, José M Del Casar, Ma Daniela Corte, Luis O González, Miguel Bongera, Antonio M Merino, Germán Juan, Raúl Obregón, Enrique Martínez, Francisco J Vizoso.   

Abstract

BACKGROUND: Despite the increasing use of breast-conserving therapy, modified radical mastectomy retains an important role in primary as well as in salvage treatment of breast cancer. Nevertheless, a significant number of patients will eventually develop a local recurrence (LR). AIMS: To identify the potential prognostic factors at the time of the first isolated LR, and to compare the expression of several parameters of the molecular biology of breast carcinomas by primary tumors and paired isolated LRs.
METHODS: We analyzed the medical records from 1,087 women who underwent mastectomy for breast cancer, out of which 98 developed LRs as the first manifestation of tumor progression. We investigated the prognostic value of various classical prognostic factors, at the time of mastectomy as well as when the diagnosis of LR was made. In addition, by using tissue microarrays and immunohistochemical techniques, we analyzed the expression of estrogen (ER), progesterone (PR) and androgen receptors (AR), ki67, p53, c-erbB-2 and apolipoprotein D in primary tumors and paired isolated LRs from a subset of patients (n = 25).
RESULTS: Patients who developed distant metastases as well as patients with local recurrent disease showed a significantly higher percentage of larger tumors, node-positive status and higher tumoral grade than patients without evidence of tumoral recurrence. Furthermore, patients with LR had a better outcome compared with those with distant metastases, although the former received less frequently adjuvant systemic therapy and/or radiotherapy. Tumor size, histological grade, ER and PR status, and a shorter disease-free interval (<12 months) were significantly associated with overall survival amongst mastectomized patients that developed isolated LR. There was a significant concordance between primary tumors and LRs regarding the expression of the following factors: ER, PR and p53. However, we were not able to demonstrate similar findings for AR, c-erbB-2 and ki67. In addition, ER, PR and p53 status in the LRs were significantly associated with a poorer overall survival.
CONCLUSIONS: Based on classical clinicopathological factors as well as on some new biological parameters we have been able to identify subgroups of mastectomized patients with LR differing in their prognosis. Thus, at the present time it would be possible to select group of patients candidates for further and individualized therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850244     DOI: 10.1007/s10549-006-9310-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

2.  Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?

Authors:  Hakan Mersin; Kaptan Gülben; Uğur Berberoğlu; Mete Yazi; Gökçe Acun; Volkan Kinaş; Sükrü Erdoğan
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

3.  PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY.

Authors:  Ljubica Radmilović Varga; Natalija Dedić Plavetić; Paula Podolski; Davor Mijatović; Ana Kulić; Damir Vrbanec
Journal:  Acta Clin Croat       Date:  2021-03       Impact factor: 0.780

4.  Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Maja Sirotković-Skerlev; Marina Barić; Damir Vrbanec
Journal:  Pathol Oncol Res       Date:  2014-08-06       Impact factor: 3.201

5.  Follow-up may not be beneficial after treatment of grade 1 breast cancer.

Authors:  M Kontos; D Allen; D T Trafalis; G Jones; H Garmo; L Holmberg; H Hamed
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

6.  Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

Authors:  José M del Casar; Guillermo Carreño; Luis O González; Sara Junquera; Salomé González-Reyes; José M González; Miguel Bongera; Antonio M Merino; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-30       Impact factor: 4.553

7.  Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up?

Authors:  Nesrine Mejri; H Boussen; S Labidi; F Benna; M Afrit; K Rahal
Journal:  Ther Adv Med Oncol       Date:  2015-05       Impact factor: 8.168

8.  Predictive risk factors for sentinel lymph node metastasis using preoperative contrast-enhanced ultrasound in early-stage breast cancer patients.

Authors:  Jianghua Qiao; Juntao Li; Lina Wang; Xiaoxia Guo; Xiaolin Bian; Zhenduo Lu
Journal:  Gland Surg       Date:  2021-02

9.  Differential prognostic indicators for locoregional recurrence, distant recurrence, and death of breast cancer.

Authors:  Rungnapa Chairat; Adisorn Puttisri; Asani Pamarapa; Jirause Moollaor; Chamaiporn Tawichasri; Jayanton Patumanond
Journal:  ISRN Oncol       Date:  2013-11-26

Review 10.  Tamoxifen Resistance: Emerging Molecular Targets.

Authors:  Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.